US · NEOG
Neogen Corporation
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Lansing, MI 48912
- Website
- neogen.com
Price · as of 2025-05-31
$9.53
Market cap 2.44B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $34.12 | +258.03% |
| Intrinsic Value(DCF) | $2.03 | -78.7% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $9.27 | $37.81 | $12.38 | $2.73 | $7.43 |
| 2012 | $9.92 | $33.85 | $5.72 | $2.95 | $3.44 |
| 2013 | $14.31 | $34.27 | $4.82 | $3.48 | $5.76 |
| 2014 | $16.59 | $37.27 | $8.66 | $3.87 | $7.62 |
| 2015 | $21.36 | $35.80 | $8.07 | $4.53 | $7.42 |
| 2016 | $20.70 | $37.93 | $7.49 | $4.98 | $7.65 |
| 2017 | $25.11 | $37.57 | $5.29 | $5.75 | $8.68 |
| 2018 | $41.80 | $45.95 | $2.28 | $7.50 | $10.80 |
| 2019 | $35.31 | $43.48 | $1.20 | $8.05 | $6.93 |
| 2020 | $40.94 | $44.47 | $1.87 | $8.68 | $5.14 |
| 2021 | $43.77 | $47.04 | $2.29 | $9.52 | $11.21 |
| 2022 | $21.42 | $37.78 | $1.59 | $9.16 | $9.05 |
| 2023 | $22.50 | $40.59 | $7.76 | $4.67 | $0.00 |
| 2024 | $16.80 | $30.96 | $0.14 | $4.44 | $0.00 |
| 2025 | $5.08 | $34.12 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Neogen Corporation's (NEOG) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $34.12
- Current price
- $9.53
- AI upside
- +258.03%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.03
-78.7% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NEOG | Neogen Corporation | $9.53 | 2.44B | +258% | -79% | — | — | -1.01 | 0.53 | 1.23 | -2.01 | -0.01 | -2.73 | 47.10% | 1.05% | -122.06% | -41.88% | 0.27% | -27.33% | 0.44 | 0.13 | 3.32 | 1.62 | -0.84 | 1146322.00% | -320.00% | -3914.00% | -4.21% | 0.33 | -1.38% | 0.00% | 0.00% | 0.00% | 200.15 | -40.68 | 2.11 | 0.67 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| BLFS | BioLife Solutions, Inc. | $24.20 | 1.17B | +49% | -55% | -73% | — | — | 2.89 | 11.18 | -103.07 | — | 2.89 | 64.56% | -12.61% | -12.61% | 0.00% | -4.52% | 0.00% | 0.03 | -4.48 | 5.23 | 5.23 | -1.18 | -4318.00% | 1697.00% | 28653.00% | 1.87% | 0.88 | 7.49% | 0.00% | — | 0.00% | -79.66 | 48.04 | 10.04 | 18.23 |
| CNMD | CONMED Corporation | $46.00 | 1.42B | +64% | -60% | -94% | -57% | 30.20 | 1.38 | 1.03 | 12.53 | — | -3.99 | 53.87% | 9.47% | 3.42% | 4.72% | 4.69% | 2.03% | 0.81 | 4.19 | 2.14 | 0.92 | 4.49 | -6455.00% | 518.00% | -195.00% | 10.62% | 0.54 | 8.22% | 1.74% | 52.60% | 7.88% | 17.02 | 14.68 | 1.61 | 1.97 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| NTLA | Intellia Therapeutics, In… | $13.78 | 1.6B | +45% | -49% | — | — | -3.22 | 2.49 | 24.73 | -3.27 | — | 2.49 | 76.47% | -651.67% | -609.85% | -67.26% | -110.87% | -51.06% | 0.14 | — | 5.08 | 4.42 | 0.15 | -2743.00% | 1692.00% | 0.00% | -21.19% | -3.36 | -89.17% | 0.00% | 0.00% | 4.97% | -2.99 | -3.71 | 19.46 | 0.53 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| OPK | OPKO Health, Inc. | $1.20 | 921.24M | +2,047% | -57% | — | +48% | -4.21 | 0.75 | 1.56 | -20.44 | -1.44 | 3.55 | 61.01% | -36.08% | -37.20% | -17.14% | -14.89% | -10.92% | 0.33 | -2.16 | 3.97 | 3.13 | -0.89 | 29113.00% | -1490.00% | -848.00% | -20.10% | -1.22 | -13.88% | 0.00% | 0.00% | 3.09% | -4.53 | -5.20 | 1.64 | -0.35 |
| TLRY | Tilray Brands, Inc. | $7.87 | 796.82M | -67% | -67% | — | — | -0.19 | 0.28 | 0.51 | -0.23 | -0.03 | 0.57 | 29.29% | -277.93% | -266.25% | -88.71% | -84.34% | -68.11% | 0.22 | -55.23 | 2.46 | 1.35 | -0.05 | 65170.00% | 484.00% | 11348.00% | -30.24% | -0.34 | -4.97% | 0.00% | 0.00% | 12.04% | -0.22 | -3.87 | 0.60 | -5.74 |
| UPB | Upstream Bio, Inc. | $7.68 | 415.02M | +226% | +2% | -60% | — | -7.31 | 0.98 | 193.67 | 0.12 | -17.44 | 0.98 | 100.00% | -3281.18% | -2650.04% | -36.23% | 67.14% | -20.97% | 0.00 | — | 44.63 | 43.93 | 4.17 | 4190.00% | -42.00% | 5677.00% | -13.00% | -5.51 | 51.53% | 0.00% | 0.00% | 64.98% | 0.12 | 0.16 | -4.06 | 23.29 |
| ZBIO | Zenas BioPharma, Inc. | $26.35 | 1.1B | -12% | -81% | — | +1,012% | -1.98 | 1.00 | 62.26 | 0.23 | -0.69 | 1.00 | -2682.78% | -3277.76% | -3139.76% | -361.99% | 109.71% | -71.66% | 0.00 | — | 6.21 | 6.12 | 1.95 | 28763.00% | -9000.00% | 29221.00% | -38.49% | -2.09 | 80.20% | 0.00% | 0.00% | 90.91% | 0.23 | 0.32 | -7.69 | 1.30 |
About Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
- CEO
- Mikhael Nassif
- Employees
- 2.92K
- Beta
- 1.98
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.03 ÷ $9.53) − 1 = -78.7% (DCF, example).